HLA-A and classic Hodgkin lymphoma: To distinguish these possibilities, we analysed the impact of HLA‐A*02 and non‐HLA‐A*02 molecules on EBV latency‐II antigen‐specific effector CD8+ T cell immunity in EBV+cHL.